Stock Forecast

  Oxurion NV ( OXUR.BR) Stock. Should you Buy or Sell?    $ 0.32

0.01 (4.23 %)



Oxurion NV Analysis

Updated on 08-08-2022
Symbol OXUR.BR
Price $0.32
Beta 0.889
Volume Avg. $197.49 thousand
Market Cap $16.25 M
52 Week Range $0.285 - $2.59


Oxurion NV opened the day at $0.32 which is +'4.23 % on yesterday's close. Oxurion NV has a 52 week high of $2.59 and 52 week low of $0.285, which is a difference of $2.305. We like to see positive, upward trending shares, preferably with momentum. Market capitalization is $16.25 M and total net profit is $1128000 which means the company is trading at 14.41 times profit to market capitalization. Theoretically, if you were to buy Oxurion NV for $16.25 M, it would take 15 years to get your money back. Oxurion NV are in the Biotechnology space which will have a sweet spot and industry standard for net profit multiples.



Price Chart


1 D | All


Financials




Oxurion NV Stock Forecast - Is Oxurion NV a Buy or Sell?


DCF ScoreStrong Buy
ROE ScoreSell
ROA ScoreSell
DE ScoreNeutral
PE ScoreStrong Sell
PB ScoreStrong Buy
Overall RecommendationNeutral

Growth and Value


PE Ratio -0.250
Dividend Yiel 0.000
Net Profit Margin -11.304


Valuing Oxurion NV


Price Book Value Ratio -11.260 Price To Book Ratio -11.260
Price To Sales Ratio 2.830 Price Earnings Ratio -0.250


How liquid is Oxurion NV


Current Ratio 1.229
Quick Ratio 0.915


Debt


Debt Ratio 1.059 Debt Equity Ratio -18.538
Long Term Debt To Capitalization 1.146 Total Debt To Capitalization 1.098



Latest news about Oxurion NV






About Oxurion NV


CEO : Dr. Patrik De Haes
Sector : Healthcare
Industry : Biotechnology

Website : https://www.oxurion.com

Exchange : Brussels

Description :

Oxurion NV, a biopharmaceutical company, develops and commercializes medicines for the treatment of eye diseases in Belgium and internationally. Its lead product is JETREA for the treatment of vitreomacular adhesion/vitreomacular traction. The company also develops THR-149, a plasma kallikrein inhibitor, which is in Phase II clinical trials for the treatment of diabetic macular edema (DME); and THR-687, an integrin antagonist which is in Phase II clinical trials for the treatment of DME. It has collaboration agreements with Bicycle Therapeutics, INC Research, and Galapagos NV. The company was formerly known as ThromboGenics NV and changed its name to Oxurion NV in September 2018. Oxurion NV was founded in 1991 and is headquartered in Leuven, Belgium.


Instagram

[instagram-feed]

My Newsletter

Sign Up For Updates & Newsletters